PUBLISHER: Allied Market Research | PRODUCT CODE: 1641780
PUBLISHER: Allied Market Research | PRODUCT CODE: 1641780
Latanoprost Market By Type , By Indication By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
The latanoprost market was valued at $1.3 billion in 2023, and is projected to reach $1.6 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.
Latanoprost is a medication primarily used in the treatment of glaucoma and ocular hypertension. It is classified as a prostaglandin analog, and works by increasing the outflow of fluid from the eye, which helps to lower intraocular pressure. Latanoprost is often prescribed to reduce the risk of damage to the optic nerve, a common complication of glaucoma, which can lead to vision loss if left untreated.
Increase in number of individuals diagnosed with glaucoma and ocular hypertension globally drives the growth of the latanoprost market. As these conditions are leading causes of vision loss, their rising prevalence fuels the market growth. As per a 2023 study published by the National Institutes of Health, approximately 70 million individuals are suffering from glaucoma worldwide. In addition, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that as the global population ages, the incidence of age-related eye conditions is expected to rise. Older adults are more likely to experience increased intraocular pressure, which directly boosts the demand for medications like latanoprost. Moreover, rise in awareness about eye health and the importance of regular eye check-ups among both patients and healthcare providers contributes to earlier detection and treatment of glaucoma, leading to higher latanoprost market adoption. Furthermore, the availability of generic latanoprost products at a lower cost has expanded the treatment options for patients, driving the growth of the market by increasing affordability and access to the drug. However, side effects and adverse reactions associated with latanoprost such as eye irritation, changes in eye color, and potential systemic effects hamper the market growth. In addition, availability of alternative medications for glaucoma, such as other prostaglandin analogs (e.g., travoprost and bimatoprost) or non-prostaglandin therapies, significantly restrains the market growth. On the contrary, ongoing advancements in ophthalmic drug formulations and delivery systems improve the effectiveness of treatments like latanoprost, making it a more attractive option for patients. Innovations, such as sustained-release formulations, enhance patient compliance and are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global latanoprost market size is segmented into type, indication, distribution channel, and region. On the basis type, the market is bifurcated into branded drug and generic drug. Depending on indication, it is segregated into open angle glaucoma and ocular hypertension. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By type, the branded drug segment is expected to dominate the market from 2024 to 2033.
On the basis of indication, the open-angle glaucoma segment is anticipated to exhibit highest growth during the forecast period.
Depending on distribution channel, the retail pharmacies segment is projected to grow at a notable pace throughout the forecast period.
Region wise, North America is likely to emerge as the most lucrative market for latanoprost in the coming years.
Competition Analysis
Competitive analysis and profiles of the major players in the global latanoprost market include Pfizer Inc., Thea Pharma Inc., Sun Pharmaceutical Industries Limited, Alcon, Taj Pharmaceuticals Limited, Viatris Inc., Apotex Inc., Wellona Pharma, Santen Pharmaceutical Co., Ltd., and Somerset Pharma LLC. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Type
- Branded Drug
- Generic Drug
By Indication
- Open Angle Glaucoma
- Ocular Hypertension
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Pfizer Inc.
- Thea Pharma Inc.
- Sun Pharmaceutical Industries Limited
- Alcon
- Taj Pharmaceuticals Limited
- Viatris Inc.
- Apotex Inc.
- Wellona Pharma
- Santen Pharmaceutical Co., Ltd.
- Somerset Pharma LLC
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
CHAPTER 4: LATANOPROST MARKET, BY TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
- 4.2. Branded Drug
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Generic Drug
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
CHAPTER 5: LATANOPROST MARKET, BY INDICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
- 5.2. Open Angle Glaucoma
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Ocular Hypertension
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
CHAPTER 6: LATANOPROST MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Providers
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
CHAPTER 7: LATANOPROST MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Indication
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Latanoprost Market
- 7.2.6.1. Market Size and Forecast, By Type
- 7.2.6.2. Market Size and Forecast, By Indication
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Latanoprost Market
- 7.2.7.1. Market Size and Forecast, By Type
- 7.2.7.2. Market Size and Forecast, By Indication
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Latanoprost Market
- 7.2.8.1. Market Size and Forecast, By Type
- 7.2.8.2. Market Size and Forecast, By Indication
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Indication
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Latanoprost Market
- 7.3.6.1. Market Size and Forecast, By Type
- 7.3.6.2. Market Size and Forecast, By Indication
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. France Latanoprost Market
- 7.3.7.1. Market Size and Forecast, By Type
- 7.3.7.2. Market Size and Forecast, By Indication
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. UK Latanoprost Market
- 7.3.8.1. Market Size and Forecast, By Type
- 7.3.8.2. Market Size and Forecast, By Indication
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Italy Latanoprost Market
- 7.3.9.1. Market Size and Forecast, By Type
- 7.3.9.2. Market Size and Forecast, By Indication
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. Spain Latanoprost Market
- 7.3.10.1. Market Size and Forecast, By Type
- 7.3.10.2. Market Size and Forecast, By Indication
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Latanoprost Market
- 7.3.11.1. Market Size and Forecast, By Type
- 7.3.11.2. Market Size and Forecast, By Indication
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Indication
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Latanoprost Market
- 7.4.6.1. Market Size and Forecast, By Type
- 7.4.6.2. Market Size and Forecast, By Indication
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. China Latanoprost Market
- 7.4.7.1. Market Size and Forecast, By Type
- 7.4.7.2. Market Size and Forecast, By Indication
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Latanoprost Market
- 7.4.8.1. Market Size and Forecast, By Type
- 7.4.8.2. Market Size and Forecast, By Indication
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. Australia Latanoprost Market
- 7.4.9.1. Market Size and Forecast, By Type
- 7.4.9.2. Market Size and Forecast, By Indication
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. South Korea Latanoprost Market
- 7.4.10.1. Market Size and Forecast, By Type
- 7.4.10.2. Market Size and Forecast, By Indication
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Latanoprost Market
- 7.4.11.1. Market Size and Forecast, By Type
- 7.4.11.2. Market Size and Forecast, By Indication
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Indication
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Latanoprost Market
- 7.5.6.1. Market Size and Forecast, By Type
- 7.5.6.2. Market Size and Forecast, By Indication
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. Saudi Arabia Latanoprost Market
- 7.5.7.1. Market Size and Forecast, By Type
- 7.5.7.2. Market Size and Forecast, By Indication
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. South Africa Latanoprost Market
- 7.5.8.1. Market Size and Forecast, By Type
- 7.5.8.2. Market Size and Forecast, By Indication
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Latanoprost Market
- 7.5.9.1. Market Size and Forecast, By Type
- 7.5.9.2. Market Size and Forecast, By Indication
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Thea Pharma Inc.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Sun Pharmaceutical Industries Limited
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Alcon
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Taj Pharmaceuticals Limited
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Viatris Inc.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Apotex Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Wellona Pharma
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Santen Pharmaceutical Co., Ltd.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Somerset Pharma LLC
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
